Multiple Myeloma Protocols
Please check with your physician for additional protocols and/or information.
1. S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
One of the standard treatments for High Risk Multiple Myeloma is the combination of bortezomib, lenalidomide and dexamethasone (RVD). Elotuzumab is an experimental cancer drug. It is currently being tested in cancer patients. There are laboratory results that suggest that RVD might work better if elotuzumab is added.
2. S1304: A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
The purpose of this study is to find out what effects, good and/or bad, adding the drug carfilzomib to regular treatment with dexamethasone has on you and your disease. We would like to compare a higher dose of carfilzomib to the lower dose that is usually used to find out which is better. The lower dose of carfilzomib is approved for treatment of your cancer. The higher dose is experimental. Therefore, carfilzomib is experimental for this study.
3. E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
The purpose of this study is to find out what effects (good and bad) the use of the drug lenalidomide has on you and your multiple myeloma, and to compare this with patients that receive no therapy. Currently, the accepted treatment for asymptomatic myeloma is to receive no therapy. However, not all patients with asymptomatic (smoldering) myeloma have the same outcome. There are 3 groups of patients as identified by the Mayo clinic group that have different predicted outcomes. Because the 3 groups can have very long delays between the identification of smoldering myeloma and the requirement for treatment, not all patients are eligible for this study. Only patients with ”high-risk” smoldering myeloma are considered eligible for this study as these are all patients whose risk of developing myeloma that requires therapy is the highest.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133.